Sector Expert: Francois Brisebois

Oppenheimer & Co.

Francois Brisbois is managing director and senior analyst at Oppenheimer & Co. Inc. covering biotechnology. Prior to joining Oppenheimer, he was a senior research analyst at Craig-Hallum Capital covering biotechnology and biopharmaceuticals. He previously worked at Laidlaw Capital Markets as a senior analyst covering biotechnology and specialty pharmaceuticals and started his Wall Street career at healthcare specialty firm Summer Street Research Partners. Brisebois holds a bachelor's degree in molecular biology from Colgate University and a Master of Science in pharmaceutical sciences from University of Montreal.



Recent Interviews

Coverage Initiated on Synthetic Cannabinoid Bioscience Company, an 'Exciting, Undiscovered Story' (6/29/17)
beakers blacknblue630.jpg

Laidlaw & Company initiated coverage with a Buy rating and target price of $18 on a company that is repurposing an approved cannabinoid to fulfill unmet medical needs.

Recent Quotes

"DRRX already exceeded enrollment in its Phase 1b NASH trial."

— Francois Brisebois, Craig-Hallum Capital (3/4/20)
more >

"DRRX's Phase 2a DUR-928 study in AH showed efficacy data and safety."

— Francois Brisebois, Laidlaw & Company (9/18/19)
more >

"Recent developments at DRRX led to a substantial influx of capital."

— Francois Brisebois, Laidlaw & Company (8/2/19)
more >

"Its partnership with Gilead could add visibility to DRRX's DUR-928."

— Francois Brisebois, Laidlaw & Company (7/22/19)
more >

"DRRX's capital raise takes care of financing overhang on the stock."

— Francois Brisebois, Laidlaw & Company (6/27/19)
more >

"We are encouraged by DRRX's clinical timeline remaining on track."

— Francois Brisebois, Laidlaw & Company (5/13/19)
more >

"DRRX's current valuation is an interesting buying opportunity."

— Francois Brisebois, Laidlaw & Company (3/8/19)
more >

"We are encouraged by DRRX's decision to fully respond to the CRL."

— Francois Brisebois, Laidlaw & Company (2/28/19)
more >



Due to permission requirements, not all quotes are shown.